
    
      The management of acute coronary syndrome has changed in recent years as reflected in the new
      Clinical Practice Guidelines of the European Society of Cardiology for the management of ACS
      with or without ST segment elevation, with the development and increased accessibility of the
      angiography and percutaneous coronary intervention and the arrival of the new antiplatelet
      (Prasugrel and Ticagrelor).

      The ACS encompasses several clinical entities where dual antiplatelet therapy remains the
      basis of antiplatelet therapy and one of the mainstays of treatment. But the emergence of
      Prasugrel and Ticagrelor have changed the classical management with aspirin plus clopidogre
    
  